Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J

06:48 AM EDT, 10/13/2026 (MT Newswires) -- Genmab (GMAB) said Tuesday that Q3 worldwide net sales of DARZALEX, including its subcutaneous formulation, totaled $4.24 billion, as reported by Johnson & Johnson (JNJ). It said U.S. sales reached $2.53 billion, while sales in the rest of the world were $1.71 billion. Genmab said it receives royalties on worldwide net sales of both intravenous and subcutaneous formulations under its exclusive global licensing agreement with J&J for the development, manufacturing and commercialization of daratumumab.